Management of PCR-Positive, Toxin-Negative C. difficile Results

Diagnostic Considerations

The Infectious Diseases Society of America recommends that patients with positive C. difficile PCR but negative toxin EIA should generally not be treated with antibiotics, as they likely represent colonization or "excretors" rather than true infection, unless specific high-risk clinical features are present 1, 2
PCR detects C. difficile genetic material with 93-94% sensitivity but cannot distinguish between active infection and harmless colonization 3
Approximately 44-55% of PCR-positive patients will be toxin-negative, representing colonization rather than true infection 3
The 30-day mortality in toxin-negative/PCR-positive patients (9.7%) is not significantly different from patients without C. difficile at all (8.6%) 1

Significant leukocytosis (high white blood cell count) is a feature suggesting true infection, according to the Clinical Infectious Diseases guidelines 1, 2
Rising serum creatinine (a measure of kidney function) is a feature suggesting true infection, according to the Clinical Infectious Diseases guidelines 1, 2
Severe diarrhea (≥6 unformed stools per 24 hours) is a feature suggesting true infection, according to the Praxis Medical Insights guidelines 3
High fever (>38.5°C) with severe abdominal pain is a feature suggesting true infection, according to the Praxis Medical Insights guidelines 2
Hypoalbuminemia (<2.5 g/dL) is a feature suggesting true infection, according to the Clinical Infectious Diseases guidelines 1
The American College of Gastroenterology recommends considering empiric treatment with oral vancomycin 125 mg four times daily for 10 days if multiple high-risk features are present 2, 3

The Centers for Disease Control and Prevention recommends maintaining contact precautions for all PCR-positive patients regardless of treatment decision 2, 4
Single-patient rooms with dedicated equipment are recommended when possible, according to the Praxis Medical Insights guidelines 2
Hand hygiene with soap and water is recommended, as alcohol-based sanitizers are less effective against C. difficile spores, according to the Praxis Medical Insights guidelines 2

The Society for Healthcare Epidemiology of America recommends discontinuing unnecessary proton pump inhibitors to reduce recurrence risk 2, 3
Implementing antimicrobial stewardship is recommended to prevent future episodes, according to the Praxis Medical Insights guidelines 2, 3
Considering alternative causes of diarrhea in PCR-positive, toxin-negative patients, including medications, enteral feeds, and other gastrointestinal conditions, is recommended, according to the Praxis Medical Insights guidelines 2

Patients presenting with minimal or non‑diarrheal stool, no evidence of fecal inflammation, or an alternative explanation for gastrointestinal symptoms are more likely colonized rather than infected and therefore do not require CDI therapy. 5

Discontinue any potentially inciting antibiotics when feasible to reduce the risk of progression to true infection. 6

Initiate empiric oral vancomycin 125 mg four times daily for 10 days when there is strong clinical suspicion for severe CDI despite a negative toxin result. [5][6]

Repeat C. difficile testing within 7 days of the initial assay during the same diarrheal episode should be avoided, as it adds only ~2 % diagnostic yield and increases false‑positive results. 7
Employ a multi‑step diagnostic algorithm that incorporates glutamate dehydrogenase (GDH) screening and toxin testing, with nucleic acid amplification testing (NAAT) used for arbitration; this approach correlates better with clinical disease than NAAT alone. 8

Routine “test of cure” is unnecessary because more than 60 % of patients remain PCR‑positive after successful clinical resolution of CDI. 5